Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
pharmaphorum7h
Gilead's HIV success and controversy: Expanding access amid criticism
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
infectiousdiseaseadvisor.com4h
Kidney Transplant Noninferior From Donors With vs Without HIV in HIV-Positive Recipients
Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.
pharmaphorum3d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
BlackDoctor23h
Essential Tips When Caring For An HIV-Positive Child
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
SciDev3d
Success of long-lasting HIV drug hinges on pricing
Unlike oral PrEP treatments, which are taken daily, the drug is administered at six-month intervals and is the longest acting injectable produced to date. In a late-stage trial, lenacapavir reduced ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
3 Absurdly Cheap Stocks That Pay High Dividends
Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...
Renal & Urology News6d
Kidney Transplant Between HIV-Positive Donors, Recipients Is Safe, Successful
Kidney transplant between donors and recipients with HIV is successful, research shows, which may help addresses the organ ...
Medscape1d
Social Adversity Tied to Poorer Mortality in Patients With Pulmonary Hypertension
Life challenges make this population very difficult to treat, but interventions that take their issues into account may ...